%PDF-1.4
%
22 0 obj
<>
endobj
19 0 obj
<>
endobj
68 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-01T18:10:20Z
2024-03-29T01:55:43-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T01:55:43-07:00
application/pdf
Heather
2001784.nov
uuid:c1b59eca-1dd1-11b2-0a00-5008278d5b00
uuid:c1b59ecd-1dd1-11b2-0a00-1e0000000000
endstream
endobj
8 0 obj
<>
endobj
9 0 obj
<>
endobj
23 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
74 0 obj
[78 0 R]
endobj
75 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.15649 Tw 9.7 0 0 10 66 713.1616 Tm
[(In rheumatology)64.9 (, observational cohort studies have been)]TJ
0.11729 Tw -1.2371 -1.2 Td
(used increasingly in the last 3 decades to address important)Tj
0.256 Tw 0 -1.2 TD
[(issues. )17.7 (W)79.8 (e have mined our longterm observational cohort)]TJ
-0.00011 Tc 0.2482 Tw T*
(study in systemic lupus erythematosus \(SLE\))Tj
0.00079 Tc 0 Tw 6.3 0 0 6.5 241.4026 680.4615 Tm
(10)Tj
-0.00011 Tc 0.2482 Tw 9.7 0 0 10 252.5396 677.1616 Tm
(to address)Tj
0 Tc 0.07291 Tw -20.468 -1.2 Td
[(questions not yet answered or not answerable by RCT)-305.1 (trials.)]TJ
-0.00011 Tc 0.0652 Tw T*
(In the area of)Tj
/TT1 1 Tf
0 Tw 5.812 0 Td
(outcomes)Tj
/TT0 1 Tf
0 Tc 0.06509 Tw [-0.3 (, our observational cohort study gave)]TJ
0.0497 Tw -5.8119 -1.2 Td
(rise to the concept of the bimodal mortality pattern in SLE)Tj
-0.0564 Tc 0 Tw 6.3 0 0 6.5 285.6275 644.4615 Tm
(11)Tj
0 Tc 9.7 0 0 10 291.5748 641.1616 Tm
(.)Tj
0.03661 Tw -24.4922 -1.2 Td
(This has opened the area of atherosclerosis as a late manifes-)Tj
-0.01401 Tw T*
(tation of SLE and may eventually give insight into the inflam-)Tj
0.00681 Tw T*
(matory-immunological mechanisms underlying the pathogen-)Tj
-0.00011 Tc 0.07809 Tw T*
[(esis of idiopathic atherosclerosis. Further)39.7 (, it has changed the)]TJ
0 Tc 0.0585 Tw T*
(approach to the treatment of SLE in that risk factor monitor-)Tj
T*
(ing and therapy is now an integral component of lupus treat-)Tj
0 Tw T*
(ment)Tj
0.0005 Tc 6.3 0 0 6.5 73.3953 560.4615 Tm
(12.)Tj
-0.00011 Tc 0.0349 Tw 9.7 0 0 10 84.0395 557.1616 Tm
(In the area of )Tj
/TT1 1 Tf
0 Tc 0 Tw [0.1 (therapy)54.9 (, )]TJ
/TT0 1 Tf
0.03481 Tw 9.2253 0 Td
(we have used cohort studies to)Tj
0.18539 Tw -12.3222 -1.2 Td
(describe the role of methotrexate)Tj
0.00079 Tc 0 Tw 6.3 0 0 6.5 188.8415 548.4615 Tm
(13)Tj
0 Tc 0.18539 Tw 9.7 0 0 10 199.3703 545.1616 Tm
(in antimalarial resistant)Tj
0.0025 Tc 0.3725 Tw -14.9866 -1.2 Td
[(lupus arthritis, prior to the publication of any RCT)-607.1 (of)]TJ
0 Tc 0.0629 Tw T*
(methotrexate in SLE, as well as the role of antimalarials)Tj
0.00079 Tc 0 Tw 6.3 0 0 6.5 277.1142 524.4615 Tm
(14)Tj
0 Tc 9.7 0 0 10 286.4549 521.1616 Tm
(in)Tj
-0.00011 Tc -0.0106 Tw -23.9644 -1.2 Td
[(skin lupus in cigarette smokers versus nonsmokers. )17.8 (W)79.7 (e)-0.1 ( used a)]TJ
0 Tc 0.1299 Tw T*
(case control design to study the safety of hormone replace-)Tj
-0.02049 Tw T*
(ment therapy in postmenopausal women with SLE)Tj
0.00079 Tc 0 Tw 6.3 0 0 6.5 248.9193 488.4616 Tm
(15)Tj
0 Tc -0.03819 Tw 9.7 0 0 10 255.2243 485.1616 Tm
[(. W)79.8 (e )-17.8 (eval-)]TJ
0 Tw -20.7448 -1.2 Td
(uated )Tj
/TT1 1 Tf
-0.00011 Tc 0.0312 Tw 2.4468 0 Td
(risk factors)Tj
/TT0 1 Tf
0 Tc 4.8393 0 Td
(for the development of coronary artery dis-)Tj
0.1496 Tw -7.2861 -1.2 Td
(ease in SLE in a cohort study)Tj
0.00079 Tc 0 Tw 6.3 0 0 6.5 176.3804 464.4616 Tm
(16)Tj
0 Tc 0.1496 Tw 9.7 0 0 10 182.6853 461.1616 Tm
(, and )Tj
/TT1 1 Tf
[0.1 (pr)36.9 (ognostic factors)]TJ
/TT0 1 Tf
-0.0002 Tc 0 Tw 10.3102 0 Td
(for)Tj
0 Tc 0.03641 Tw -23.5767 -1.2 Td
(mortality in a similar cohort study)Tj
0.00079 Tc 0 Tw 6.3 0 0 6.5 188.0329 452.4616 Tm
(17)Tj
0 Tc 9.7 0 0 10 194.3378 449.1616 Tm
(. )Tj
/TT1 1 Tf
0.03641 Tw 0.5365 0 Td
(Clinical laboratory cor-)Tj
0.0619 Tw -15.0043 -1.2 Td
[(r)37.1 (elations studies)]TJ
/TT0 1 Tf
6.9197 0 Td
(in our cohort have given rise to the concept)Tj
0.1629 Tw -6.9197 -1.2 Td
(of the serologically active, clinically quiescent patient with)Tj
-0.00011 Tc 0 Tw T*
(SLE)Tj
0.00079 Tc 6.3 0 0 6.5 71.2426 416.4616 Tm
(18)Tj
0 Tc 0.088 Tw 9.7 0 0 10 80.8269 413.1616 Tm
(and thus modifying approaches to therapy in this dis-)Tj
-0.00011 Tc 0 Tw -2.7657 -1.2 Td
(ease.)Tj
0 Tc -0.0094 Tw 1.2371 -1.2 Td
(In other words, in an era of evidence based medicine, there)Tj
-0.0318 Tw -1.2371 -1.2 Td
[(are many ways of \223knowing.\224 RCT)-200.4 (or the critical observations)]TJ
0.07539 Tw T*
(of an experienced clinician are not the sole roads to medical)Tj
0.01579 Tw T*
[(knowledge. )17.8 (T)69.8 (o promote either as such would distort the truth.)]TJ
0.01849 Tw T*
(Every question in medicine should be addressed by the medi-)Tj
0.02499 Tw T*
(um most suited to give valid answers.)Tj
/TT2 1 Tf
-0.00011 Tc 7.3196 -2.4 Td
[(MURRA)91.7 (Y)-238 (B. UROWITZ,)]TJ
/TT0 1 Tf
5.82 0 0 6 235.2055 305.1616 Tm
(MD, FRCPC,)Tj
7.76 0 0 8 125 295.1616 Tm
(Centre for Prognosis Studies in Rheumatic Diseases,)Tj
0 Tc 0 -1.25 TD
(Room 1-319B, Main Pavilion,)Tj
-0.00011 Tc T*
(399 Bathurst Street,)Tj
0 Tc T*
[(T)69.8 (oronto, Ontario, Canada M5T)-257.2 (2S8)]TJ
/TT1 1 Tf
-0.00011 Tc -9.1495 -2.5 Td
[(Addr)36.8 (ess r)36.8 (eprint r)36.8 (equests to Dr)110.7 (. Ur)36.8 (owitz.)]TJ
/TT2 1 Tf
0 Tw 9.7 0 0 10 54 223.1616 Tm
(REFERENCES)Tj
/TT0 1 Tf
0 Tc 0.02499 Tw 8 0 0 8 61 213.1616 Tm
[(1.)-875 (Buchanan )17.8 (WW)91.8 (, Kean )17.8 (WF)79.8 (. Evidence based medicine: )17.8 (The median is)]TJ
1.675 -1.25 Td
(not the message. J Rheumatol 2001; xx-xx)Tj
-1.675 -1.25 Td
[(2.)-875 (Preventative Services )17.7 (T)69.8 (ask Force. Guide to clinical preventive)]TJ
-0.00011 Tc 1.675 -1.25 Td
[(services: Report of the US Preventative Services )17.7 (T)69.7 (ask Force. 2nd)]TJ
0 Tc 33 66.421 Td
[(ed. Baltimore: )17.8 (W)39.8 (illiams and )17.8 (W)39.8 (ilkins; 1996.)]TJ
-1.675 -1.25 Td
[(3.)-875 (Benson K, Hartz )54.8 (AJ. )54.8 (A)-219.8 (comparison of observational studies and)]TJ
1.675 -1.25 Td
(randomized controlled trials. N Engl J Med 2000;243:1878-86.)Tj
-1.675 -1.25 Td
[(4.)-875 (Concato J, Shah N, Horwitz RI. Randomized controlled trials,)]TJ
1.675 -1.25 Td
(observational studies, and the hierarchy of research designs. N Engl)Tj
T*
(J Med 2000;324:1887-92.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(5.)-875.1 (Sachs H, Chalmers )17.7 (TC, Smith H Jr)54.8 (. Randomized versus historical)]TJ
0 Tc 1.675 -1.25 Td
[(controls for clinical trials. )54.8 (Am J Med 1982;72:233-40.)]TJ
-1.675 -1.25 Td
[(6.)-875 (Feinstein )54.9 (AR. )54.9 (An additional basic science for clinical medicine: I.)]TJ
1.675 -1.25 Td
[(The constraining fundamental paradigms. )54.8 (Ann Intern Med)]TJ
0 Tw T*
(1983;99:393-7.)Tj
0.02499 Tw -1.675 -1.25 Td
[(7.)-875 (Feinstein )54.9 (AR. )54.9 (An additional basic science for clinical medicine: II.)]TJ
1.675 -1.25 Td
[(The limitations of randomized trials. )54.8 (Ann Intern Med 1983;)]TJ
0 Tw T*
(99:544-50.)Tj
0.02499 Tw -1.675 -1.25 Td
[(8. )-600 (Feinstein )54.9 (AR. )54.9 (An additional basic science of clinical medicine: III.)]TJ
1.675 -1.25 Td
[(The challenges of comparison and measurement. )54.8 (Ann Intern Med)]TJ
0 Tw T*
(1983;99:705-12.)Tj
0.02499 Tw -1.675 -1.25 Td
[(9. )-600 (Feinstein )54.9 (AR. )54.9 (An additional basic science for clinical medicine: IV)128.9 (.)]TJ
1.675 -1.25 Td
[(The development of clinimetrics. )54.9 (Ann Intern Med 1983;99:843-8.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(10.)-875.1 (Lee P)110.7 (,)-0.1 ( Urowitz MB, Bookman )54.8 (AAM, et al. SLE: )54.8 (A)-219.9 (review of 1)36.7 (1)-0.1 (0)]TJ
2.175 -1.25 Td
(cases with particular reference to lupus nephritis, CNS)Tj
T*
(manifestations, infections, aseptic necrosis and prognosis. Q J Med)Tj
0 Tc 0 Tw T*
(1977;46:1-32.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (U)-0.1 (rowitz MB, Bookman )54.8 (AAM, Koehler BE, et al. )17.7 (The bimodal)]TJ
0 Tc 2.1381 -1.25 Td
[(mortality in systemic lupus erythematosus. )54.8 (Am J Med 1976;)]TJ
0 Tw T*
(60:221-5.)Tj
0.0249 Tw -2.175 -1.25 Td
[(12.)-875 (Bruce IN, Gladman DD, Urowitz MB. Detection and modification)]TJ
-0.00011 Tc 2.175 -1.25 Td
(of risk factors for coronary artery disease in patients with systemic)Tj
0 Tc T*
[(lupus erythematosus. )54.8 (A)-219.8 (quality improvement study)64.9 (. Clin Exp)]TJ
T*
(Rheumatol 1998;15:435-40.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(13.)-875.1 (Rahman P)110.7 (, Humphrey-Murto S, Gladman DD, Urowitz MB.)]TJ
0 Tc 2.175 -1.25 Td
[(Ef)17.8 (ficacy and tolerability of methotrexate in antimalarial resistant)]TJ
T*
(lupus arthritis. J Rheumatol 1998;25:243-6.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(14.)-875.1 (Rahman P)110.7 (, Gladman DD, Urowitz MB. Smoking interferes with)]TJ
0 Tc 2.175 -1.25 Td
[(ef)17.8 (ficacy of antimalarial therapy in cutaneous lupus. J Rheumatol)]TJ
0 Tw T*
(1998;25:1716-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875.1 (Kreidstein SH, Urowitz MB, Gladman DD, Gough JM. Hormone)]TJ
0 Tc 2.175 -1.25 Td
(replacement therapy in SLE. J Rheumatol 1997;24:2149-52. )Tj
-0.00011 Tc -2.175 -1.25 Td
[(16.)-875.1 (Bruce IN, Urowitz MB, Gladman DD, Hallet DC. Natural history)]TJ
0 Tc 2.175 -1.25 Td
(of hypercholesterolemia in systemic lupus erythematosus. )Tj
T*
(J Rheumatol 1999;26:2137-43.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(17.)-875.1 (Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality)]TJ
2.175 -1.25 Td
(studies in systemic lupus erythematosus. Results from a single)Tj
T*
[(centre. II. Predictor variables for mortality)64.8 (. J Rheumatol)]TJ
0 Tc 0 Tw T*
(1995;22:1265-70.)Tj
0.0249 Tw -2.175 -1.25 Td
[(18.)-875 (Gladman DD, Urowitz MB, Keystone EC. Serologically active)]TJ
2.175 -1.25 Td
[(clinically quiescent systemic lupus erythematosus. )54.9 (A)-219.8 (discordance)]TJ
T*
[(between clinical and serological features. )54.8 (Am J Med 1979;)]TJ
0 Tw T*
(66:210-5.)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT1 1 Tf
0.02499 Tw 8 0 0 8 420.9531 35.9844 Tm
[(The Journal of Rheumatology 2001; 28:1)74 (1)]TJ
0 Tw -45.8691 -0.0313 Td
(2374)Tj
ET
0 0 0 0 scn
/GS0 gs
102.25 59.08 407.5 -10.83 re
f*
0.5 w
102.25 59.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
63 0 obj
<>
endobj
73 0 obj
<>
endobj
26 0 obj
<>
endobj
27 0 obj
<>
endobj
4 0 obj
<>
endobj
5 0 obj
<>
endobj
6 0 obj
<>stream
HdVpTs͋р,1$^h& IAg]v4@y! VwÀF" 錨h
UUtTDn1fC'àVd,kZ@Q{?n nb/.AƶxU9g3P}+:=~,_Km|>g u[Z^|km7m?'Wwn { 0sܭW=3eq伿(>-=3'-+geOQNͧY}=q9MV<=FH4?Zm$LO>m~6c' r%pLETX<4߲-WXІH{X>M`&V박g}mz) ߃}@nuP0nvkݭ4QLAlZnhq|'yR(eR!FH[d2jE~#xxNw?tcUơ5DD19
.'md/!V]_)r =]J?+WtR
#9Rטi